Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor

Journal of Neurochemistry

Volumn 86, Issue 2, 2003, Pages 290-297

  Sagi, Yotam ^a   Weinstock, Marta ^b   Youdim, Moussa B H ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b HEBREW UNIVERSITY   (Israel)

Author keywords

Dopamine; Enzyme inhibition; Monoamine oxidase inhibitor; MPTP; Neuroprotection; Novel cholinesterase

Indexed keywords

(N PROPARGYLAMINOINDAN 5 YL)ETHYLMETHYLCARBAMATE; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CHOLINESTERASE INHIBITOR; DOPAMINE; DRUG METABOLITE; ENZYME; LADOSTIGIL; MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; SEROTONIN; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; CELL PROTECTION; COMORBIDITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMENTIA; DEPRESSION; DRUG ACTIVITY; DRUG SPECIFICITY; ENZYME INHIBITION; EXTRAPYRAMIDAL SYNDROME; FORCED SWIMMING TEST; HIPPOCAMPUS; LONG TERM CARE; NEUROTOXICITY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT; STRIATE CORTEX;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; BRAIN STEM; CEREBRAL CORTEX; CHOLINESTERASE INHIBITORS; CORPUS STRIATUM; DOPAMINE; ENZYME ACTIVATION; INDANS; MALE; MICE; MICE, INBRED C57BL; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; MPTP POISONING; NEUROPROTECTIVE AGENTS; NEUROTOXINS; NOREPINEPHRINE; SEROTONIN; TYROSINE 3-MONOOXYGENASE;

ANIMALIA; GYMNOMYZA SAMOENSIS;

EID: 0038155162     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2003.01801.x     Document Type: Article

References (29)

1. Barber R., Panikkar A. and McKeith I. G. (2001) Dementia with Lewy bodies: diagnosis and management. Int. J. Geriatr. Psychiatry 16, S12-S18.
2. Ben-Shachar D. and Youdim M. B. H. (1990) Selectivity of melaninized nigra-striatal dopamine neurons to degeneration in Parkinson's disease may depend on iron-melanin interaction. J. Neural Transm. Suppl. 29, 251-258.
3. Binda C., Newton-Vinson P., Hubalek F., Edmondson D. E. and Mattevi A. (2002) Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat. Struct. Biol. 9, 22-26.
4. Carlo P., Del Rio M., Violani E., Sciaba L. and Picotti G. B. (1996) Influence of culture conditions on monoamine oxidase A and B activity in rat astrocytes. Cell Biochem. Funct. 14, 19-25.
5. Corte L. D. and Tipton K. F. (1980) The turnover of the A- and B-forms of monoamine oxidase in rat liver. Biochem. Pharmacol. 29, 891-895.
6. Goridis C. and Neff N. H. (1971) Monoamine oxidase: an approximation of turnover rates. J Neurochem. 18, 1673-1682.
7. Green A. R. and Youdim M. B. H. (1975) Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration. Br. J. Pharmacol. 55, 415-422.
8. Green A. R., Mitchell B. D., Tordoff A. F. and Youdim M. B. H. (1977) Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. Br. J. Pharmacol. 60, 343-349.
9. Heikkila R. E., Duvoisin R. C., Finberg J. P. and Youdim M. B. H. (1985) Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur. J. Pharmacol. 116, 313-317.
10. Honig L. S. and Mayeux R. (2001) Natural history of Alzheimer's disease. Aging (Milano) 13, 171-182.
11. Kato T., Horiuchi S., Togari A. and Nagatsu T. (1981) A sensitive and inexpensive high-performance liquid chromatographic assay for tyrosine hydroxylase. Experientia 37, 809-811.
12. Keller R., Oke A., Mefford I. and Adams R. N. (1976) Liquid chromatographic analysis of catecholamines routine assay for regional brain mapping. Life Sci. 19, 995-1003.
13. Kindt M. V. and Heikkila R. E. (1986) Prevention of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic toxicity in mice by MDL 72145, a selective inhibitor of MAO-B. Life Sci. 38, 1459-1462.
14. Levites Y., Weinreb O., Maor G., Youdim M. B. H. and Mandel S. (2001) Green tea polyphenol (-)-Epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced dopaminergic neurodegeneration. J. Neurochem. 78, 1073-1082.
15. Maruyama W., Takahashi T., Youdim M. B. H. and Naoi M. (2002) An anti-Parkinson drug, Rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J. Neural Transm. 109, 467-481.
16. Newman S. C. (1999) The prevalence of depression in Alzheimer's disease and vascular dementia in a population sample. J. Affect. Disord. 52, 169-176.
17. Przedborski S., Kostic V., Jackson-Lewis V., Naini A. B., Simonetti S., Fahn S., Carlson E., Epstein C. J. and Cadet J. L. (1992) Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J. Neurosci. 12, 1658-1667.
18. Robert P. (2002) Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine. Curr. Med. Res. Opin. 18, 156-171.
19. Schoepp D. D. and Azzaro A. J. (1981) Specificity of endogenous substrates for types A and B monoamine oxidase in rat striatum. J. Neurochem. 36, 2025-2031.
20. Sterling J., Herzig Y., Goren T., Finkelstein N., Lemer D., Goldenberg W., Miskolcz I., Molnar S., Rantal F., Tamas T., Toth G., Zagyva A., Zekany A., Lavian G., Gross A., Friedman R., Razin M., Huang W., Krais B., Chorev M., Youdim M. B. and Weinstock M. (2002) Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease. J. Med. Chem. 45, 5260-5279.
21. Tipton K. F. and Youdim M. B. (1976) Assay of monoamine oxidase, in Monoamine Oxidase and its Inhibition (Wolstenholeme G. E. W. and Knight J., eds), pp. 393-403. Excerpta Medica, North Holland.
22. Tipton K. F., McCrodden J. M. and Youdim M. B. H. (1986) Oxidation and enzyme-activated irreversible inhibition of rat liver monoamine oxidase-B by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Biochem. J. 240, 379-383.
23. Weinstock M., Goren T. and Youdim M. B. H. (2000a) Development of a novel neuroprotective drug (TV3326) for the treatment of Alzheimer's disease, with cholinesterase and monoamine oxidase inhibitory activities. Drug Dev. Res. 50, 216-222.
24. Weinstock M., Kirschbaum-Slager N., Lazarovici P., Bejar C., Shoami E. and Youdim M. B. H. (2000b) Cell culture and in vivo neuroprotective effects of novel cholinesterase-MAO inhibitors. Derived from rasagiline as potential anti-Alzheirmer drugs. Ann. NY Acad. Sci. 939, 148-161.
25. Weinstock M., Poltyrev T., Bejar C. and Youdim M. B. H. (2002a) Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression. Psychopharmacology (Berl) 160, 318-324.
26. Weinstock M., Gorodetsky E., Wang R. H., Gross A., Weinreb O. and Youdim M. B. (2002b) Limited potentiation of blood pressure response to oral tyramine by brain-selective monoamine oxidase A-B inhibitor, TV-3326 in conscious rabbits (1). Neuropharmacology 43, 999-1005.
27. Youdim M. B. and Weinstock M. (2002) Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline. Mech. Ageing Dev. 123, 1081-1086.
28. Youdim M. B. H. and Tipton K. F. (2002) Rat striatal monoamine oxidases inhibition by I-deprenyl and rasagiline: its relationship to 2-phenylethylaminenduced stereotypy and parkinson's disease. Parkinsonism Rel. Disord. 8, 247-253.
29. Youdim M. B. H., Gross A. and Finberg J. P. M. (2001) Rasagiline [N-Propargyl-1R (+)-aminoindant], a selective and potent inhibitor of mitochondrial monoamme oxidase B. Br. J. Pharmacol. 132, 500-506.